Press Releases

October 27, 2021
Ocugen, Inc. Announces Submission of Investigational New Drug Application with U.S. FDA to Initiate a Phase 3 Clinical Trial Evaluating COVID-19 Vaccine Candidate COVAXIN™ (BBV152)
The Phase 3 study is designed to bridge data collected from the vaccine efficacy trial conducted in India to the U.S. population MALVERN, Pa., Oct. 27, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing novel
Additional Formats
September 1, 2021
Expert series: The truth about COVID-19 variants
(BPT) - By Shankar Musunuri, PhD, MBA, Chairman, CEO and Co-Founder, Ocugen After a summer of hope, the COVID-19 positivity rate has been spiking in the United States. Due in part to the highly transmissible and fast-spreading Delta variant, the number of cases of COVID-19 is up more than 107% vs.
Additional Formats
August 6, 2021
Ocugen Provides Business Update and Second Quarter 2021 Financial Results
         Conference Call and Webcast Today at 8:30 a.m. ET Rolling regulatory submission to Health Canada completed and review process initiated; U.S. FDA talks continue Multiple milestones achieved across regulatory and supply chain to support potential commercialization of pipeline assets The
Additional Formats
Displaying 1 - 10 of 42